The methylation of the three genes RASSF1A, calcitonin-related polypeptide alpha (CALCA), and adenovirus E1A-associated cellular p300 transcriptional co-activator (EP300) enabled differentiation between ovarian cancer patients and healthy controls with a sensitivity of 90% and a specificity of 87%, while the methylation of RASSF1A and progesterone receptor-Prospero homeobox protein 1 (PGR-PROX) discriminated between ovarian cancer and benign tumors with a sensitivity of 80% and a specificity of 73% [197]. This evidence concerns the gene RASSF1 and benign neoplasm.